Lietz Katherine
Center for Advanced Heart Failure and Transplantation, Yale University School of Medicine, New Haven, Connecticut 06520-8017, USA.
J Card Surg. 2010 Jul;25(4):462-71. doi: 10.1111/j.1540-8191.2010.01050.x. Epub 2010 May 30.
Long-term left-ventricular assist device (LVAD) support as destination therapy (DT) is a promising new alternative for the growing population of patients with advanced heart failure. In this article, we summarize the clinical trials that led to the approval of LVAD use as DT in the US national policies regulating candidate selection and DT center accreditation. We review current guidelines for candidate selection, clinical tools to assess candidate operative risk, and outcomes of DT.
长期使用左心室辅助装置(LVAD)作为终末期治疗(DT),对于越来越多的晚期心力衰竭患者来说是一种很有前景的新选择。在本文中,我们总结了那些促使LVAD在美国国家政策中被批准用于终末期治疗的临床试验,这些政策涉及候选者选择和终末期治疗中心认证。我们回顾了当前关于候选者选择的指南、评估候选者手术风险的临床工具以及终末期治疗的结果。